TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04659967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Training
Description: Participants will receive a virtual training that is tailored to age-related hearing loss, use of non-custom personal amplification devices, and communication strategies.
Study: NCT02173912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg and Amlodipine besylate 10mg (Reference)
Description: Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.~Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between.
Study: NCT01309048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips MR-guided HIFU system
Description: HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein and nerve denaturation, irreversible cell damage, and coagulative necrosis.
Study: NCT04707989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketone- Promoting Food Ingredient #1
Description: Novel proprietary food ingredient (#1) that contains precursors to naturally occurring energy molecules called ketone bodies. Promotes mildly elevated blood ketone concentrations. Mixed into a beverage.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ketone- Promoting Food Ingredient #2
Description: Previously characterized proprietary food ingredient (#2) that contains precursors to naturally occurring energy molecules called ketone bodies. Promotes mildly elevated blood ketone concentrations. Mixed into a beverage.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ketone Free Placebo
Description: Beverage that is matched to ketone-promoting food ingredient #1 beverage for appearance, taste, texture and volume. Does not contain ketones or ketone precursors.
Study: NCT02962271

Intervention type: DEVICE
Intervention: Musculoskeletal Ultrasound
Description: Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed

Intervention type: DEVICE
Intervention: Musculoskeletal Ultrasound
Description: Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
Study: NCT02173912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-30059 (Test)
Description: Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.~Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-30059 (Test)
Description: Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.~Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between.
Study: NCT01028339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Description: 2 mL/kg of 7.5% hypertonic saline associated to hydroxyethyl starch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: Mannitol
Study: NCT05688046

Intervention type: DRUG
Intervention: Immune checkpoint inhibitors plus angiogenesis inhibitors
Description: PD-(L)1-based therapy plus Bevacizumab or Anlotinib

Intervention type: DRUG
Intervention: Immune checkpoint inhibitors without angiogenesis inhibitors
Description: PD-(L)1-based therapy
Study: NCT04679701

Intervention type: DEVICE
Intervention: Amparo Confidence Socket
Description: The Amparo Confidence Socket technology takes a different approach by starting with a prefabricated socket (https://www.amparo.world/confidence-socket-en). The socket is made from a moldable thermoplastic and has the attachment point pre-assembled. This prefabricated socket is essentially an off-the-shelf product that can be heated, then molded directly to the patient's residual limb. This removes many of the intermediate steps in traditional socket fabrication. The product's molding temperature is between 60-70 ˚C but the insulation of a silicone liner between the plastic and limb ensures safe temperatures for the patient. This process is currently used in several workshops in Europe and with approximately 50 patients currently using the product. In general, it has been shown to be safe and effective in creating below-knee prosthesis.
Study: NCT03495323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: LY3300054 is a monoclonal antibody that targets programmed cell death ligand 1 (

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Prexasertib work by preventing the cancer cells from being able to repair damaged DNA (one of the building blocks of a cell) which then leads to cell death
Study: NCT02116244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Civamide Nasal Spray
Study: NCT02118012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorcyclizine HCl
Description: Chlorcyclizine HCl (75 mg twice daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorcyclizine HCl
Description: Chlorcyclizine HCl (75 mg twice daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: RBV was dosed via a weight-based regimen of 1000 mg daily\<75 kg and 1200 mg daily ≥75 kg.
Study: NCT01619683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enclomiphene citrate
Description: 12.5 mg, 1 capsule, daily, oral. After 6 weeks of treatment, subjects will remain on 12.5 mg/day if their morning testosterone level is greater than 300 ng/dL. If a subject's testosterone is less than 300 ng/dL, the subject's dose will be increased to 25 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo capsule per day, oral
Study: NCT01967212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Game-based swallow biofeedback
Description: The intervention are divided into two parts：~1. Traditional swallowing training 30 min by speech therapist.~2. Game-based biofeedback combined with Mendelsohn's maneuver and effortful swallow 30 min by investigator.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Swallow training without biofeedback
Description: The intervention are divided into two parts：~1. Traditional swallowing training 30 min by speech therapist.~2. Mendelsohn's maneuver and effortful swallow without biofeedback 30 min.
Study: NCT01455142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Single injection of each formulation. The dose level will be 0.5 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Single injection of each formulation. The dose level will be 0.5 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
Study: NCT02986568

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical cancer
Description: If tumor sized ≥ 5cm, undergo neoadjuvant chemotherapy with Cisplatin before surgery. (40mg/m2 on day 1 of each 7 day cycle for 5 cycles), then perform Fusion TMMR after neoadjuvant chemotherapy with cisplatin as above.~If tumor size \< 5cm, perform Fusion Total mesometrial resection (TMMR)~After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy.~If not, no adjuvant therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine cancer
Description: Perform Fusion Peritoneal mesometrial resection (PMMR).~After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy.~If not, no adjuvant therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical cancer, pelvic sidewall invasion
Description: Perform Fusion Laterally extended endopelvic resection (LEER).~After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy. Patients with primary disease will be treated with adjvuant chemotherapy. In case of recurrent disease, bevacizumab, paclitaxel, and cisplaitn will be administered regardless of the pathologic report (bevacizumab 15mg/kg on day 1, paclitaxel 135mg/m2 on day 1, and cisplatin 50mg/m2 on day 2, of each 21 day cycle).~If not, no adjuvant therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-cervical cancer, pelvic sidewall invasion
Description: Perform Fusion Laterally extended endopelvic resection (LEER).~After surgery, appropriate adjuvant chemotherapy will be administered depending on the tumor type.
Study: NCT03362073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Application of ketamine using continuous intravenous infusion method during 5 days~* Ketamine 100mg/2ml + 5% Dextrose water or Normal saline 98 ml mixed fluid~* Dose schedule: 0.05mg/kg/hr -\> 0.10mg/kg/hr -\> ... -\> 0.5mg/kg/hr (increase dose at a rate of 0.05mg/kg/hr every 8 hours)
Study: NCT00895596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB80380
Description: Total treatment period: 12 weeks, followed by 24 weeks of treatment with adefovir dipivoxil 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB80380
Description: Total treatment period: 12 weeks, followed by 24 weeks of treatment with adefovir dipivoxil 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB80380
Description: Total treatment period: 12 weeks, followed by 24 weeks of treatment with adefovir dipivoxil 10mg
Study: NCT03486795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M1 stimulation
Description: stimulating primary motor cortex with anodal stimulation on right primary motor cortex and cathodal stimulation on left primary motor cortex

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M1 stimulation
Description: stimulating primary motor cortex with anodal stimulation on right primary motor cortex and cathodal stimulation on left primary motor cortex

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMC stimulation
Description: stimulating premotor cortex with anodal stimulation on right premotor cortex and cathodal stimulation on left supraorbital area

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: sham stimulation over both primary motor cortex and premotor cortex
Study: NCT01737788

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical occlusion
Description: Women were randomized to receive cervical occlusion or no cervical occlusion in addition to a cervical cerclage (McDonald or Shirodkar cerclage). Cervical occlusion was performed with interrupted or continuous sutures, placed approximately 1 cm deep on each lip, and 0.5 cm apart with a nylon 2-0/3-0 suture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical occlusion
Description: Women were randomized to receive cervical occlusion or no cervical occlusion in addition to a cervical cerclage (McDonald or Shirodkar cerclage). Cervical occlusion was performed with interrupted or continuous sutures, placed approximately 1 cm deep on each lip, and 0.5 cm apart with a nylon 2-0/3-0 suture.
Study: NCT01396720

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluvoxamine
Description: Fluvoxamine 100mg daily, 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citalopharm
Description: Citalopharm 20mg daily, 7 days
Study: NCT04468204

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SinuSonic Device
Description: A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham SinuSonic Device
Description: Sham positive expiratory pressure intervention using the SinuSonic Device.
Study: NCT01735513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-aortic embolic protection management system; Embol-X
Description: The Embol-X system is positioned within the aorta to capture emboli, such as blood clots or tissue fragments, to prevent them from traveling through a patient's bloodstream during TAVI. The EMBOL-X system features a small, expandable, polyester-mesh filtration system that is placed inside the aorta above the aortic clamp during open-heart surgery or transaortic TAVI procedures, where it captures particles in the bloodstream that otherwise might have remained in the patient's circulatory system. A recent presentation characterized the removal of aortic cross-clamps as creating in some patients embolic showers which have the potential to cause neurocognitive complications, stroke and other organ damage. In documented procedures, 97% of EMBOL-X system filters showed detectable captured embolic matter, visible proof that the system is removing potentially dangerous emboli from the bloodstream.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-aortic embolic protection management system; Embol-X
Description: The Embol-X system is positioned within the aorta to capture emboli, such as blood clots or tissue fragments, to prevent them from traveling through a patient's bloodstream during TAVI. The EMBOL-X system features a small, expandable, polyester-mesh filtration system that is placed inside the aorta above the aortic clamp during open-heart surgery or transaortic TAVI procedures, where it captures particles in the bloodstream that otherwise might have remained in the patient's circulatory system. A recent presentation characterized the removal of aortic cross-clamps as creating in some patients embolic showers which have the potential to cause neurocognitive complications, stroke and other organ damage. In documented procedures, 97% of EMBOL-X system filters showed detectable captured embolic matter, visible proof that the system is removing potentially dangerous emboli from the bloodstream.
Study: NCT04803097

Intervention type: DIAGNOSTIC_TEST
Description: We took slit-lamp-adapted anterior segmental photography from pediatric cataract eyes at baseline，1 week, 2 weeks, 1 month, 3 months, and 6 months postoperatively.
Study: NCT02237950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole oral tablets 500mg
Description: One tablet taken orally twice daily for seven consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metronidazole oral tablets 500mg
Description: One tablet taken orally twice daily for seven consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% SPL7013 Gel
Description: 5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: 5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks
Study: NCT03638024

Intervention type: DIAGNOSTIC_TEST
Intervention: Maternal plasma cell free fetal DNA levels
Description: Measurement Maternal plasma cell free fetal DNA levels in both groups (study and control groups)

Intervention type: DIAGNOSTIC_TEST
Intervention: Maternal plasma cell free fetal DNA levels
Description: Measurement Maternal plasma cell free fetal DNA levels in both groups (study and control groups)
Study: NCT01761318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Preparation and labelling of Investigational Medicinal Product:~Liraglutide will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide - Placebo
Description: Preparation and labelling of Investigational Medicinal Product:~Liraglutide - Placebo will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial.
Study: NCT00677209

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Injection of autovaccine (Autovaccine Symbiopharm)
Description: increasing dosage schedule, six different concentrations, application over six weeks, 2 weeks break, another six weeks, 2 weeks break, than challenge with inhalative house dust mite extract
Study: NCT02180880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin and Oxcarbazepine
Description: Subjects will take pregabalin for the duration of 2 weeks. The dosage will be increased from 75 mg twice to 150 mg twice a day.~Subjects will stop pregabalin for 1 week and take oxcarbazepine 150mg twice.
Study: NCT01270282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM-101 0.81 mg/mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04529928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carillon Mitral Contour System
Description: Eligible subjects will be implanted with the Carillon Device, utilizing the Carillon Mitral Contour System. The device is a permanent implant in the coronary sinus/great cardiac vein, designed to cinch the mitral annulus. The implant procedure is minimally invasive, conducted via catheter placement.
Study: NCT03078205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The dual therapy
Description: TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The triple therapy
Description: TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM
Study: NCT02640703

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix + Prevenar 13
Description: Different time of application

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix + Prevenar 13
Description: Different time of application
Study: NCT02430766

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Unresectable Lymph Node Metastases guide with ultrasound or/and CT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Study: NCT04093609

Intervention type: GENETIC
Intervention: XIST gene deletion
Description: detection of XIST gene deletion by fluorescence in situ hybridization

Intervention type: GENETIC
Intervention: XIST gene deletion
Description: detection of XIST gene deletion by fluorescence in situ hybridization
Study: NCT01767688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3102
Description: Single dose of 25 mg of MK-3102 (1 x 25 mg capsule) administered orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3102
Description: Single dose of 25 mg of MK-3102 (1 x 25 mg capsule) administered orally on Day 1.
Study: NCT03211988

Intervention type: DRUG
Group type: OTHER
Intervention: Entinostat
Description: Dose is 5 mg orally every week (days 1, 8, 15, and 22) of a 28 day treatment cycle. Study drug should be taken in the morning and on an empty stomach, at least 2 hours after a meal and at least 1 hour before the next meal. Tablets should be taken whole and not crushed.
Study: NCT02118311

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T Regulatory cells
Description: Fixed dose of nTreg cells will be infused on day 0 of transplant after the umbilical cord blood cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30mg/m\^2 IV over 1 hour on days -6 through -2 from transplant
Study: NCT01633203

Intervention type: DRUG
Intervention: epirubicin + cisplatin + capecitabine polychemotherapy
Description: EPIRUBICIN (LKM)at a dose of 50 mg/m2 over 15 minutes is administered every 21 days.~CISPLATIN (LKM) at a dose of 60 mg/m2 over 4 hours is administered every 21 days. Patients must receive standardized hydration per protocol.~CAPECITABINE (Xeloda®) at a dose of 625 mg/m2 BID (i.e. 1250 mg/m2/day) 30 minutes after meals from day 1 to day 21 of every cycle of chemotherapy.~Antiemetic therapy:~* Dexamethasone 8 mg IV and Ondansetron (LKM) 8 mg IV o Granisetron (Kytril®) prior to chemotherapy~* Rescue Ondansetron (LKM) 8 mg IV will be given during 24-hour hospitalization in case of emesis~* Symptomatic antiemetic therapy with thiethylperazine will be prescribed.~Loperamide will be prescribed in case of diarrhea.
Study: NCT04018560

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Al-Anon Intensive Referral (AIR)
Description: AIR is intended to facilitate Al-Anon participation.
Study: NCT04563728

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Surveillance camera(s)
Description: the mock camera intervention is for testing whether the impression of surveillance would have the effect to reduce the recidivism of elder abuse in home settings; 2) whether less costly options (mock cameras) are as effective as surveillance camera(s) in reducing the recidivism of elder abuse; 3) feasibility and acceptability of surveillance camera(s)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Surveillance camera(s)
Description: the mock camera intervention is for testing whether the impression of surveillance would have the effect to reduce the recidivism of elder abuse in home settings; 2) whether less costly options (mock cameras) are as effective as surveillance camera(s) in reducing the recidivism of elder abuse; 3) feasibility and acceptability of surveillance camera(s)
Study: NCT00898924

Intervention type: GENETIC
Intervention: molecular diagnostic method
Study: NCT02118311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30mg/m\^2 IV over 1 hour on days -6 through -2 from transplant
Study: NCT00898924

Intervention type: GENETIC
Intervention: mutation analysis